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Abstract
Background—Poor response to erythropoiesis stimulating agents (ESA) is associated with
morbidity and mortality among dialysis patients. It is unclear whether the risk associated with poor
ESA response during dialysis extends beyond kidney transplantation. We examined pretransplant
ESA response and its effect on allograft failure and mortality.
Methods—The cohort included all adult Medicare recipients from the United States Renal Data
System who had received a kidney transplant during years 2000–2007 and had at least 6 months of
hemodialysis immediately prior to transplant. ESA hyporesponsiveness was primarily defined as a
monthly ESA dose ≥75,000 units and hematocrit ≤33% for at least 3 consecutive months in the
pretransplant period. Crude and adjusted Cox-proportional hazards models and Kaplan-Meier
methods were used to estimate the effect of ESA hyporesponsiveness on allograft failure and all-
cause mortality.
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Results—The study group consisted of 36,450 patients; 1,004 exhibited hyporesponsiveness.
The adjusted hazard ratios for allograft failure and mortality post-transplant were 1.23 (95%CI
1.10, 1.42) and 1.61 (1.43, 1.81), respectively, supporting that poor ESA response during
hemodialysis is associated with adverse post-transplant outcomes.
Conclusions—ESA hyporesponsiveness may be useful in identifying potential allograft
recipients who are at high-risk for subsequent morbidity and mortality, and may benefit from more
intensive pre- and post-transplant follow-up.
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Introduction
Kidney transplantation is the preferred form of renal replacement therapy for individuals
with end-stage kidney disease (ESKD). While overall allograft survival has improved over
the past two decades (1, 2), early allograft loss remains an important cause of morbidity and
mortality (3, 4). Previous studies assessing risk factors for allograft loss have identified
donor specific variables (5–8) and recipient-dependent characteristics that are either not
modifiable (9–11) or only apparent just prior to transplantation (12, 13). With an average
waiting time for deceased donor kidney transplant ranging from 3–5 years (14), the
pretransplant dialysis period provides a substantial exposure interval to examine the effect of
dialysis specific interventions on post-transplant outcomes. Dialysis associated medications
represent an understudied area with regard to post-transplant outcomes.
Erythropoiesis stimulating agents (ESA) are commonly used to treat anemia in patients
receiving dialysis (15). In the United States, the average weekly ESA dose ranges between
17,000–18,000 units (1). Their use has likely benefited allograft survival by reducing the
need for blood transfusions (1), and consequently reducing pretransplant sensitization (16).
Enthusiasm for ESA use has been tempered by studies reporting increased risk associated
with high target hemoglobin levels (17–20) and administration of large doses of ESA (21).
Subsequent analyses of these studies have shown that diminished responsiveness to ESA
most strongly predicts morbidity and mortality in chronic kidney disease and dialysis
patients (22–24). While the leading explanation for these observations has been that ESA
hyporesponsiveness is an indicator of underlying inflammation in the dialysis population it
is not well understood if the effect persists post-transplant.
Chronic inflammation has been known to increase the risk of adverse outcomes in the
transplant population (25). Assessment of ESA response may therefore identify high-risk
future transplant recipients.
A previous study demonstrated an increased risk of graft failure associated with ESA
hyporesponsiveness (26). While the findings were compelling, the study cohort ran from
1995–2002, and may not be reflective of contemporary patients undergoing transplantation;
furthermore, the study used a fixed definition of ESA hyporesponsiveness. To take this
observation further we examined the effect of diminished responsiveness to ESA in the
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pretransplant period on post-transplant morbidity and mortality in a contemporary cohort of
transplant recipients, using varying definitions of ESA hyporesponsiveness. Specifically, we
hypothesized that ESA hyporesponsiveness during the dialysis period may predict allograft
failure after transplantation. Furthermore, we postulated that there would be a graded dose-
response impact on post-transplant outcomes within the group of individuals hyporesponsive
to ESA. We tested these hypotheses in a large retrospective cohort of transplant recipients
who were receiving hemodialysis immediately prior to transplant.
Results
Baseline cohort characteristics
There were 36,450 participants that met inclusion criteria, the majority were White, male,
and had a deceased donor type. There was a high degree of HLA (human leukocyte antigen)
mismatch and a low PRA (panel reactive antibody) in the study population. Of the included
individuals there were 31,632 receiving at least 1 unit of ESA and with monthly hematocrit
values available for bivariate analysis. Using the ESA dose limit of ≥75,000 units we
identified 1,004 hyporesponsive individuals that remained hyporesponsive for 3 months
prior to transplant. Hyporesponsive individuals were more often of younger age, African-
American, had longer hemodialysis vintage, and were more likely to have a hemodialysis
catheter (Table 1). Similar results were seen for individuals that were hyporesponsive for 6
months using the same ESA dose criteria (n=363). The mean ESA monthly dose for
individuals with a hematocrit of <=33% group was higher when compared to those with a
hematocrit of >33% (see digital content Figure 1).
The mean ESA doses for each month prior to transplant increased consistently from month 6
to month 1 pretransplant in the <33% hematocrit group, whereas opposite results where seen
in the >33% hematocrit group (see supplemental digital content Table 1). The most common
cause of ESKD was diabetes mellitus (34%), followed by hypertension (24%), and
glomerulonephritis (9%).
Allograft failure & loss
Allograft failure occurred in 17% of the study population (n=6,070). When including
participant’s death as a cause of allograft failure (allograft loss) the event occurrence
increased to 32% (n=11,666). Crude and adjusted Cox models showed the ESA
hyporesponsive group was more likely to experience allograft failure and loss when
compared to those who did not meet criteria for hyporesponsiveness regardless of the
duration of hyporesponsiveness (Table 2). Kaplan-Meier methods showed similar results
(Figure 1). The results were not affected when censoring at 3 years post-transplant or when
including all available follow-up time.
Mortality
All-cause mortality was 21% (n=7,679) for the entire study population. The most common
causes of death were cardiovascular events (39%), infectious complications (21%) and
malignancies (8%). ESA hyporesponsiveness was associated with increased all-cause
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mortality regardless of duration of hyporesponsiveness (Table 2). The probability of survival
was lower in the hyporesponsive group (Figure 2).
Analyses using alternate ESA hyporesponsiveness definitions
Our results were sensitive to changing ESA minimum monthly dose parameters for the
definition of ESA hyporesponsiveness. In both adjusted and unadjusted analyses the hazard
ratios for allograft failure, loss and all-cause mortality increased consistently as the
minimum monthly ESA dose given increased with one exception. In case of marked
hyporesponsiveness for 3 months (ESA ≥200,000) and allograft failure the effect estimate
decreased and was not statistically significant (Table 3). A separate analysis using lower
dose ESA (<75,000), showed no meaningful increase in risk in those with a hematocrit
response of <33%, but increasing estimated risk as the ESA dose increased with the same
exception noted above (see supplemental digital content Table 2).
Discussion
In this cohort of individuals receiving kidney transplantation, we observed that diminished
ESA response during the hemodialysis period was associated with allograft failure, loss, and
death after a kidney transplant. The presence of low hemoglobin and high ESA dose during
the 3 to 6 months immediately prior to transplantation increased the risk of allograft loss and
failure by at least 39% in crude analyses; adjustment for demographic and medical factors
did not meaningfully attenuate the point estimate. Kaplan-Meier curves demonstrated that
the effect appeared relatively soon post-transplant and the trend continued over the entire
observation period. Sensitivity analysis using more restrictive definitions of the exposure
suggested a dose-response effect. The hazards ratio increased in size as the definition of
hyporesponsiveness included a larger dose of ESA.
To our knowledge, this is the first study to demonstrate a dose-related effect of pretransplant
ESA hyporesponsiveness on post-transplant survival. Our findings are consistent with the
growing body of literature demonstrating that persistent treatment-resistant anemia may be
associated with poor outcomes in patients with kidney disease (26). We did not attempt to
address the mechanism behind this association, though it is possible that mechanisms
postulated for studies in chronic kidney disease might also apply to our results in patients
receiving a kidney transplant. Diminished response to ESA is likely to be a marker of
underlying inflammation. Inflammation has been observed to predict morbidity and
mortality in the general (27–30), chronic kidney disease (31), dialysis (32–35), and
transplant populations (25, 36). While inflammation has been routinely assessed by
abnormal laboratory parameters such as elevated C-reactive protein & ferritin or low
albumin, there is a growing consensus that the clinical scenario of low hemoglobin and high
ESA dose also reflects a state of inflammation. Patient comorbidities thought to contribute
to inflammation include occult infections (37–41), dialysis catheter use (42), poor dialysate
water quality (43–45), uremia (46), intravenous iron use (47–54), and hepicidin-mediated
disorders of iron homeostasis and hematopoiesis (55–57). However, many of these sources
of inflammation, such as uremia, infections and catheter use, would be absent or less
common in the transplant population.
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ESA hyporesponsive patients in this study and other studies have considerably higher
cumulative exposure to ESA. Direct adverse effects of high doses of ESA cannot be
excluded as a potential factor for the resulting adverse outcomes. Experimental models and
clinical studies have shown that ESA induce physiological changes in two key areas; the
coagulation cascade and the blood pressure. Among hemodialysis patients, ESA promotes
activation of the coagulation cascade at a dose as small as 2000 units three times weekly
(58). Additionally, cultured human endothelial cells exposed to recombinant erythropoietin
showed a dose dependent increase in expression of tissue factor, an important mediator of
the coagulation cascade (59). Dialysis patients with hemoglobin > 13 and exposed to ESA
demonstrate thrombocytosis (60). ESA administration increases platelet reactivity,
thrombopoiesis, and endothelial activation (61). ESA also increase systemic arterial blood
pressure, most likely from increased blood volume and impaired blood nitric oxide
production (62), though only one of the randomized studies of ESA administration showed a
significant increased risk of hypertension (63). Taken in sum, ESA use may lead to a
physiologic environment that would promote adverse cardiovascular events. However, it is
unclear whether these effects would linger into the post-transplant period. A 1-year follow-
up study of the Normal Hematocrit Study found that risks between the two treatment groups
were identical after the discontinuation of the study intervention (19).
The findings of this study should be interpreted in the context of the following limitations.
While basic demographic and medical variables at baseline suggested that the two groups
were roughly equivalent, information was not available on many potentially important time-
dependent variables such as serum albumin and serum C-reactive protein. The lack of
measures on such variables clouds our ability to determine what the underlying cause of the
poor treatment response may be. Additionally our study was not designed to examine a
direct effect from ESA, thus we cannot determine whether the association that we have
observed might be partially or completely attributable to ESA exposure. We also did not
have information on ESA use after the transplant occurred and cannot exclude the possibility
that ESA use during this period could have impacted the observed effects. Recent studies,
documenting ESA use in the post transplantation period have demonstrated varying effects
(64–66). One study in the immediate post-transplant period did not demonstrate an
association of ESA use with transplant (kidney) function (64). A second study showed that
treatment with ESA was associated with mortality throughout the post-transplant period
(65). Another potential confounding factor is the unknown effect of blood transfusions; data
on transfusion rates among those who were ESA resistant was not reliably available and was
not included in any analysis.
The findings of the study should not be interpreted as a reason to avoid or delay kidney
transplantation among patients found to be hyporesponsive to ESA. It is well established
that among patients with end-stage renal disease, transplantation remains the best option for
long-term survival; even among individuals with diminished responsiveness to ESA, the
benefits of transplantation likely outweigh the risks of continued hemodialysis. Rather, such
patients would benefit from close surveillance during the post-transplant period with the
goal of reducing their risk of adverse events.
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Our study had several important strengths that should be noted. The assembled cohort,
representative of the transplant population in the United States (US), allows for high
generalizability of the results among US transplant and dialysis centers. Additionally, the
sample size afforded the opportunity to vary the definition of the exposure for multiple
analyses; the findings of which were highly consistent across the board. Lastly the study
potentially opens up novel areas for investigation—pretransplant medications as potentially
modifiable predictors of transplant outcomes. Strategies to identify individuals in the
pretransplant period who are at high risk for allograft loss and death could prevent
significant morbidity after kidney transplantation. Indirectly such strategies could help to
reduce the problematic shortage of organs.
In summary we conclude that ESA response appears to be a strong predictor of poor post-
transplant outcomes. Additional confirmatory studies are necessary. In the meantime the
finding of low ESA response may help identify patients for greater surveillance and to
optimize therapy during the pre and post-transplant period.
Methods
Study population
Participants were ≥18 years of age recipients of a first kidney transplant between January 1st
2000 and December 31st 2007 included in the United States Renal Data System (USRDS).
This database provides baseline demographic information and follow-up data for all
Medicare patients with ESKD receiving dialysis or a kidney transplant. The included
participants were required to have at least 6 months of in-center hemodialysis immediately
prior to the transplant date and to have a minimum of 12 months follow-up after transplant.
Participants had Medicare as a primary payer source in order to obtain the information on
ESA dosing from monthly billing claims. All participants had a monthly billing claim for
ESA administration for 6 months prior to transplant. Recipients of combined organs were
excluded. Follow-up data was available through the end of 2008. The study was reviewed
and approved by the University of North Carolina Institutional Review Board.
Exposure definition
ESA hyporesponsiveness was defined as a total ESA dose ranging from ≥75,000 to
≥200,000 units per month and a preceding corresponding hematocrit value of ≤33%
(approximately equivalent to a hemoglobin of 11 g/dl) for 3 or 6 consecutive months
immediately prior to the transplant date. The ESA total dose criteria was varied to examine
the potential for a dose-related response and to ensure the results were consistent.
Additionally, since ESA dosing is based on weight, and we were expecting a wide range of
weight measurements in this population, this precaution decreased the potential of
misclassifying insufficient ESA doses, particularly given that participant’s weight was only
available at the time of dialysis start as recorded in the End Stage Renal Disease Medical
Evidence Report (also known as CMS-2728 form). To simplify reporting, results are
presented using the ESA hyporesponsiveness definition dose of ≥75,000 units and a
hematocrit of ≤33% (for either 3 or 6 months) as the main exposure and result differences
for analyses using variable ESA dosing criteria will be mentioned when appropriate.
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The primary outcome was allograft failure, defined as one of the following: 1) evidence of a
second transplant, 2) return to dialysis or 3) transplant nephrectomy at any time after
transplant. Secondary outcomes were 1) allograft loss, defined as death with a functioning
graft in addition to all causes of allograft failure, and 2) mortality defined as patient death
from any cause after transplant.
Covariates
Age, gender, race and ethnicity were obtained from the CMS-2728 form. Hemodialysis
vintage was derived using the date of start of dialysis and the date of the first transplant.
Hemodialysis catheter information was examined during the 6 months immediately prior to
transplant. Medicare billing claims for hemodialysis catheter placement (Current Procedural
Terminology codes 36558, 36565, 36575, 36581, 36489, & 36491) in combination with
access type listed at the time of initiation of hemodialysis were used to ascertain
hemodialysis catheter status. Diabetes status was obtained from co-morbidity information
listed both at the initiation of hemodialysis and at the time of the first transplant. Donor type
was defined as either living or deceased, as listed at the time of transplant and reported to
USRDS by the United Network for Organ Sharing.
Statistical analysis
Participant characteristics are presented for the full cohort and according to ESA response
status using proportions and frequencies for categorical variables, and means with standard
deviations for continuous variables. Medians with interquartile range are reported for
skewed distributions. Independent group t-tests, Wilcoxon-Mann-Whitney, and chi-square
tests were used for bivariate comparisons as appropriate. Kaplan-Meier methods were used
to present the probability of allograft failure, loss and all-cause mortality in a time to event
analysis. Log-rank tests were used to compare survivor functions. Cox proportional hazards
models were used in crude and adjusted analysis to test for covariate effects. Final models
for the analyses planned were determined using a backwards-stepwise modeling strategy.
The models were adjusted for recipient age, gender, weight, race/ethnicity, hemodialysis
duration, hemodialysis catheter, diabetic status, and donor type. Proportionality was tested
with Wald and partial Likelihood Ratio tests in a series of models using time-varying
variables. The ESA minimum total monthly dose parameter for the hyporesponsiveness
definition was adjusted from values ranging between 75,000 – 200,000 units for multiple
analyses. For each analysis participants were censored at the time the outcome was present
or at 3 years after transplant whichever occurred earlier. Additionally a separate analysis
was conducted including all available follow-up time. All analyses were performed using
SAS statistical software (SAS Institute Inc., SAS® 9.2, Cary, NC, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kaplan-Meier estimates of allograft survival according to ESA response, for allograft failure
(present if: a second transplant, or return to dialysis, shown in A) and allograft loss (present
if: a second transplant, or return to dialysis, or death with a functioning graft shown in B) at
3 (left) and 6 (right) months of ESA hyporesponsiveness. The probability of allograft loss
and failure was higher in the ESA hyporesponsive group (Log-Rank p <0.01).
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Kaplan-Meier estimates of patient survival according to ESA response comparing 3 months
(A) to 6 months (B) of persistent ESA hyporesponsiveness. The probability of survival was
lower in the ESA hyporesponsive group for both 3 and 6 months periods (Log-Rank p
<0.01).
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Table 1
Baseline cohort characteristics & distribution for ESA hyporesponsiveness among covariates





Yes (n=1004) No (n=30628)
Male gender 22415 (62) 603 (60) 18639 (61) 0.62
White 20672 (57) 500 (50) 17387 (58) <0.01
African-American 13041 (36) 438 (44) 10884 (36) <0.01
Asian 1821 (5) 42 (4) 1620 (5) 0.12
Other ‡ 916 (2) 24 (2) 737 (2) 0.19
Hispanic 5963 (17) 127 (13) 5037 (16) <0.01
Deceased donor type 29094 (80) 800 (80) 24497 (80) 0.92
Diabetic 15269 (42) 364 (36) 12885 (42) <0.01
Hemodialysis catheter 4388 (12) 197 (20) 3558 (12) <0.01
HLA match (0–6) 2.0 ± 1.6 2.0 ± 1.6 2.0 ± 1.6 0.92
PRA (%) 6.6 ± 18.8 7.6 ± 20.1 6.6 ± 18.8 0.13
Age (18–87 years) § 46.8 ± 13.8 44.5 ± 13.3 47.0 ± 13.8 <0.01
Iron dose (mg/month) 166.7 (281.3-33.3) 166.7 (291.7-10.2) 166.7 (281.3-33.3) 0.88
Weight (40–175 kg) § 76.4 (90.9-65.0) 79.0 (95.0-67.0) 76.0 (90.0-65.0) <0.01
Hemodialysis vintage (0.5–33 years) 3.6 (5.3-2.2) 4.0 (5.7-2.6) 3.6 (5.3-2.2) <0.01
*
Values reported as %, means ± standard deviations, or median (interquartile range) as appropriate.
†
ESA hyporesponsiveness was defined as hematocrit ≤33% and erythropoiesis stimulating agent dose ≥75K units/month for 3 consecutive months.
31,632 patients had received at least 1 unit of ESA and had documented monthly hematocrit values.
‡
Includes Native-Americans and unknown race.
HLA: human leukocyte antigen PRA: panel reactive antibody.
§
Age and weight at the start of hemodialysis.
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